Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2023; 15(4): 460-476
Published online Apr 27, 2023. doi: 10.4254/wjh.v15.i4.460
Recent advances in recurrent hepatocellular carcinoma therapy
Yu-Xue Gao, Qi-Qi Ning, Peng-Xiang Yang, Yuan-Yue Guan, Peng-Xiang Liu, Meng-Lu Liu, Lu-Xin Qiao, Xiang-Hua Guo, Tong-Wang Yang, De-Xi Chen
Yu-Xue Gao, Qi-Qi Ning, Peng-Xiang Yang, Yuan-Yue Guan, Peng-Xiang Liu, Meng-Lu Liu, Lu-Xin Qiao, Xiang-Hua Guo, Tong-Wang Yang, De-Xi Chen, Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing 100069, China
Yu-Xue Gao, Qi-Qi Ning, Peng-Xiang Yang, Yuan-Yue Guan, Peng-Xiang Liu, Meng-Lu Liu, Lu-Xin Qiao, Xiang-Hua Guo, De-Xi Chen, Beijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing 100069, China
Tong-Wang Yang, Academician Workstation, Changsha Medical University, Changsha 410219, Hunan Province, China
Tong-Wang Yang, Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha 410219, Hunan Province, China
Author contributions: Gao YX and Ning QQ contributed equally to this work; Yang PX, Guan YY, Liu PX, Liu ML Qiao LX, and Guo XH searched the references and polished the manuscript; Yang TW and Chen DX designed the review; all authors have read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 82073676; Chinesisch-Deutsches Forschungsprojekt in Sonderprogramm zu COVID-19, No. C-0012; Key Programs of Beijing Municipal Education Commission of China, No. KZ202010025037; Third Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes, No. Jing 2019-6; and Fourth Round of Public Welfare Development and Reform Pilot Projects of Beijing Municipal Medical Research Institutes, No. Jing 2021-10.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: De-Xi Chen, PhD, Professor, Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, No. 8 Youanmenwai, Youanmen Street, Fengtai District, Beijing 100069, China. dexichen@ccmu.edu.cn
Received: September 19, 2022
Peer-review started: September 19, 2022
First decision: December 1, 2022
Revised: December 20, 2022
Accepted: March 24, 2023
Article in press: March 24, 2023
Published online: April 27, 2023
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, and up to 50%-70% of individuals may experience a relapse of the illness in the liver after 5 years. This review will provide novel approaches to improve the prognosis of patients with recurring HCC with the apparent lack of data to guide the clinical treatment. Neoadjuvant and/or adjuvant therapy methods potentially elevate the opportunity of cure in refractory patients with recurrent HCC and contribute to a better long-term prognosis.